• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Identification and Characterization of Influenza Virus Entry Inhibitors Through Dual-Myxovirus High-Throughput Screening

tetano

Editor, Senior Moderator
J Virol. 2016 Jun 1. pii: JVI.00898-16. [Epub ahead of print]
[h=1]Identification and Characterization of Influenza Virus Entry Inhibitors Through Dual-Myxovirus High-Throughput Screening.[/h] Weisshaar M[SUP]1[/SUP], Cox R[SUP]1[/SUP], Morehouse Z[SUP]1[/SUP], Kyasa S[SUP]2[/SUP], Yan D[SUP]1[/SUP], Oberacker P[SUP]1[/SUP], Mao S[SUP]2[/SUP], Golden JE[SUP]3[/SUP], Lowen AC[SUP]4[/SUP], Natchus MG[SUP]2[/SUP], Plemper RK[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A virus (IAV) infections cause major morbidity and mortality, generating an urgent need for novel antiviral therapeutics. We recently established a dual-myxovirus high-throughput screening protocol, that combines a fully replication-competent IAV-WSN and a respiratory syncytial virus reporter strain for the simultaneous identification of IAV-specific, paramyxovirus-specific, and broad-spectrum inhibitors. Here, this protocol was applied to a screening campaign, assessing a diverse chemical library with over 142,000 entries. Focusing on IAV-specific hits, we obtained a hit rate of 0.03% after cytotoxicity testing and counterscreening. Three chemically distinct hit classes with nanomolar potency and favorable cytotoxicity profiles were selected. Time-of-addition, minigenome, and viral entry studies demonstrated that these classes block hemagglutinin (HA)-mediated membrane fusion. Antiviral activity extends to an insolate of the 2009 pandemic and, in one case, another group 1 subtype. Target identification through biolayer interferometry confirmed binding of all hits to HA. Resistance profiling revealed two distinct escape mechanisms: primary-type resistance associated with reduced compound binding and secondary resistance with unaltered binding. Secondary resistance was mediated, unusually, through two different pairs of cooperative mutations, each combining a mutation eliminating the membrane-proximal stalk N-glycan with a membrane-distal change in HA1 or HA2. Chemical synthesis of an analog library combined with in silico docking extracted a docking pose of the hit classes. Chemical interrogation spotlights IAV HA as a major druggable target for small-molecule inhibition. Our study identifies novel chemical scaffolds with high developmental potential, outlines diverse routes of IAV escape from entry inhibition, and establishes a path towards structure-aided lead development.
[h=4]IMPORTANCE:[/h] This study is one of the first to apply a fully replication-competent third generation IAV reporter strain to a large-scale HTS drug discovery campaign, allowing multi-cycle infection and screening in physiologically relevant human respiratory cells. A large number of potential druggable targets was thus chemically interrogated, but mechanistic characterization, positive target identification, and resistance profiling demonstrated that three chemically promising and structurally distinct hit classes selected for further analysis all block HA-mediated membrane fusion. Viral escape from inhibition could be achieved through primary and secondary resistance mechanisms. In silico docking predicted compound binding into a microdomain located at the membrane-distal site of the prefusion HA stalk that was also previously suggested as target site for chemically unrelated HA inhibitors. This study identifies an unexpected chemodominance of the HA stalk microdomain for small-molecule inhibitors in IAV inhibitor screening campaigns and highlights a novel mechanism of cooperative resistance to IAV entry blockers.
Copyright ? 2016, American Society for Microbiology. All Rights Reserved.


PMID: 27252534 [PubMed - as supplied by publisher]
 
Back
Top Bottom